There are two primary types of diabetes: type 1 and type 2. Both types result in high levels of blood sugar levels, which may manifest itself through any of the following symptoms: increased thirst and an increased need to urinate; feeling edgy, tired, and sick to your stomach; and having an increased appetite (but loss of weight). In addition, other symptoms may include: repeated or hard-to-heal infections of the skin, gums, vagina, or bladder; blurred vision; tingling or loss of feeling in the hands or feet; and dry, itchy skin. If left uncontrolled, high blood sugar may result in a variety of serious complications.

Glycosylated Protein
Many of these complications are the result of glycosylated protein (GP). GP simply means that sugar (glucose) has attached itself to protein. For example, blood sugar can attach itself to the protein in your red blood cells’ hemoglobin and form glycosylated hemoglobin (HbA1c). Virtually all proteins are glycosylated to some degree. However, if this process continues to excess, eventually you end up with compounds called Advanced Glycosylation End Products (AGE). These AGE become permanent fixtures in our cells. AGE impregnated cells are very reactive and react with one another, and other proteins. In the case of blood capillaries, they can result in the walls of the capillaries thickening, eventually causing the vessels to be blocked off. This is the underlying cause of kidney complications (nephropathy) and eye complications (retinopathy). Unfortunately, the more blood sugar, the more glycosylated proteins.

Sorbitol
Another mechanism by which complications in diabetes result is excessive cellular sorbitol (a type of sugar-alcohol). Many cells in the body do not rely on insulin for glucose uptake. When you have hyperglycemia, you actually get high sugar levels inside these cells, which cause sorbitol to be produced in high concentrations. Intracellular sorbitol disrupts the pressure balance between the inside and outside of the cell, causing water to enter. This swelling of nerve cells is what is believed to be, at least in part, responsible for the nerve damage (neuropathy) caused by diabetes. (This does not mean that if you consume sorbitol in foods that it will have the same effect—it won’t.)

Type 1 Diabetes
Type 1, immune-mediated diabetes (formerly called insulin-dependent diabetes), is a disease that affects the way your body uses food. In type 1 diabetes your body destroys the cells in the pancreas that produce insulin, usually leading to a total failure to produce insulin. It typically starts in children or young adults who are slim, but can start at any age. Without insulin, your body cannot control blood levels of sugar. And without insulin, you would die. So people with type 1 diabetes give themselves at least one shot of insulin every day. An estimated 500,000 to one million Americans have this type of diabetes today. Conventional medical treatment for type 1 diabetes includes insulin injections, and diet regulation.

Type 2 Diabetes
Type 2 diabetes used to be called non-insulin-dependent diabetes. The most common type of diabetes, it affects about 15 million Americans. Nine out of ten cases of diabetes are type 2. It usually occurs in people over 45 and overweight, among other factors. When you have type 2 diabetes, your body does not make enough insulin—or your body still makes insulin but can’t properly use it. Without enough insulin, your body cannot move blood sugar into the cells. Sugar builds up in the bloodstream. Conventional medical treatment for type 2 diabetes includes any of the following, alone or in combination: insulin injections, oral drugs, or diet alone.

Following is a discussion about dietary supplements that may help diabetics to gain greater control over their blood sugar levels, reduce the long-term detrimental effects of high blood sugar levels, or both.

Chromium
Chromium levels can be below normal in patients with diabetes.1,2 In a randomized, placebo-controlled study3, 180 men and women with type 2 diabetes were divided into three groups and supplemented with: 1) placebo, 2) 200 mcg chromium daily, or 3) 1,000 mcg chromium daily (from chromium picolinate for both doses). Subjects continued to take their normal medications and were instructed not to change their normal eating and living habits. The results were that both doses of supplemental chromium had significant beneficial effects on HbA1c, glucose, insulin, and cholesterol variables, although the benefits were greater with the higher dose.

Other studies show that taking chromium picolinate orally can decrease fasting blood glucose, decrease HbA1c levels, decrease triglyceride levels, and increase insulin sensitivity in people with type 2 diabetes.4,5 Some evidence also suggests that chromium picolinate might decrease weight gain and fat accumulation in type 2 diabetes patients who are taking a sulfonylurea.6 Higher chromium doses (1,000 mcg) might be more effective and work more quickly.7 Higher doses might also reduce triglyceride and total serum cholesterol levels in some patients.8,9 Additional research demonstrated that chromium picolinate might have the same benefits in patients with type 1 diabetes10 and in patients who have diabetes secondary to corticosteroid use.11

Banaba
Banaba is the common name for Lagerstroemia speciosa, a traditional herbal medicine used among diabetics in the Philippines.12 Research done on Banaba extract has demonstrated that it has an “insulin-like principle” as well as an ability to reduce blood sugar. At least one component of this insulin-like principle is thought to be corosolic acid, although Banaba also contains other like candidates including ellagitannins, lagerstroemin, flosin B, reginin A. As a matter of fact, a recent study identified ellagitannins from Banaba as activators of glucose transport.13

One of the Banaba studies was conducted on hereditary diabetic mice. The results showed blood sugar increases were suppressed, and the level of serum insulin and the amount of urinary excreted glucose were also lowered in mice fed Banaba extract. The researchers suggested Banaba extract has beneficial effects on control of blood levels of glucose in non-insulin dependent diabetes mellitus.14

Twelve diabetic subjects taking 48 mg of the Banaba extract were tested in a randomized, double-blind crossover study. This study confirmed that a Banaba extract promotes normal blood glucose metabolism in people with type 2 diabetes, and also showed that Banaba extract’s benefits were sustained for several weeks even after discontinuation of the supplement.15

Another crossover, placebo-controlled clinical study with 24 subjects found similar results. Specifically, Banaba extract was effective in reducing blood glucose levels even in short-term (4 weeks) treatment, with no signs of adverse effects. Furthermore, even a one-time dose leaves a memory-effect for blood glucose control. Compared to the placebo group, a statistically significant drop in the average blood glucose level is observed with the administration of Banaba extract.16

Gymnema Sylvestre
Animal studies have demonstrated that the herb Gymnema sylvestre is capable of lowering blood glucose levels, improving glucose utilization, and increasing insulin levels in diabetes.17,18,19,20

The latter benefit was found to be a function of Gymnema’s apparent ability to repair/regenerate beta cells, the parts of the pancreas responsible for producing insulin.21

Of greater significance to diabetic patients is the research conducted on humans. In one study, 22 type 2 diabetic patients received Gymnema for 18–20 months, as a supplement to the conventional oral drugs. During Gymnema supplementation, the patients showed a significant reduction in blood glucose, glycosylated hemoglobin and glycosylated blood proteins; and conventional drug dosage could be decreased. As a matter of fact, five of the 22 diabetic patients were able to discontinue their conventional drug and maintain their blood glucose homeostasis with Gymnema alone. The researchers concluded, “These data suggest that the beta cells may be regenerated/repaired in type 2 diabetic patients on [Gymnema] supplementation. This is supported by the appearance of raised insulin levels in the serum of patients after [Gymnema] supplementation.”22

In a similar study, Gymnema was administered to 27 patients with type 1 diabetes, who were also on insulin therapy. The results were that insulin requirements came down together with blood glucose and glycosylated hemoglobin and glycosylated blood protein levels. Blood fats also returned to near normal levels with Gymnema therapy. Type 1 diabetic patients who were just on insulin therapy (no Gymnema), showed no significant reduction in serum lipids, glycosylated hemoglobin or glycosylated blood protein when followed up after 10–12 months. The researchers of this study concluded, “Gymnema therapy appears to enhance endogenous insulin, possibly by regeneration/revitalization of the residual beta cells in insulindependent diabetes mellitus.23

Bitter Melon
Bitter melon (Momordica charantia) is a tropical vegetable widely cultivated in Asia, Africa and South America, and has been used extensively in traditional folk medicine as a remedy for diabetes. This traditional use has also been validated by clinical research. In one study, Bitter melon was found to significantly improve the glucose tolerance of 73 percent of patients with adult-onset diabetes (type 2).24 During another study, Bitter Melon significantly reduced blood glucose concentrations during a glucose tolerance test in type 2 diabetics.25 Other research has identified the protein component of Bitter Melon that have the blood sugar lowering effects, and those researchers have stated that it is very effective for that purpose when administered to “gerbils, langurs, and humans.”26

Alpha Lipoic Acid
A significant amount of research has been conducted on the natural antioxidant Alpha Lipoic Acid (ALA) in the treatment of diabetes. In one study, seventy-four patients with type-2 diabetes were given either a placebo, or ALA. When compared to the placebo group, those receiving the ALA had significantly greater insulin-sensitivity, and improvement in insulin-stimulated glucose disposal. The researchers logically concluded, “The results suggest that oral administration of alpha-lipoic acid can improve insulin sensitivity in patients with type-2 diabetes.”27 Another benefit of ALA use in diabetics has to do with diabetic neuropathy. In one study on type 2 diabetics, ALA treatment was associated with “a favorable effect on neuropathic deficits without causing significant adverse reactions.”28 In another two-year study, ALA “appeared to have a beneficial effect on several attributes of nerve conduction” in a group of type 2 diabetic patients.29 Additional research on diabetics has shown that ALA has been able to improve other aspects of diabetic neuropathy, 30,31 including improvements in neuropathy symptoms.32,33,34

Another important consideration is that oxidative stress caused by free radicals can exacerbate the diabetic condition. Research provides evidence that, in type 2 diabetics, treatment with ALA significantly improves antioxidant defense35—even in patients with poor blood sugar control and albuminuria (i.e., too many serum proteins in the urine).36

Finally, one of the most important benefits offered to diabetics by ALA is the fact that it has been shown to enhance the disposal of blood sugar in patients with type 2 diabetes, which gives it great potential as a blood sugar lowering agent.37 In a related study of lean and obese diabetic patients treated with ALA, the ALA prevented increases in metabolites that are typically associated with high blood sugar, and also increased blood sugar effectiveness.38

Co-enzyme Q10
Research has shown that some diabetic patients who use diet to control their blood sugar may have a deficiency of Co-enzyme Q10 (CoQ10), which may be further exacerbated by certain commonly used antidiabetic drugs. Such a deficiency of CoQ10 in the pancreas could impair aspects of energy metabolism, and the biosynthesis of insulin. Other research has also demonstrated that CoQ10 levels are lower in diabetic patients, which can cause diabetic cardiomyopathy. That same research, however, also showed that the diabetic cardiomyopathy can also be reversed by CoQ10 supplementation.40 And speaking of a cardiac condition, research has also demonstrated that CoQ10 exhibits an effective antiarrhythmic (i.e., prevents abnormal heart beat) in patients with diabetes.41

A newly discovered form of diabetes is referred to as maternally inherited diabetes mellitus and deafness (MIDD). The characteristic clinical features of MIDD are progressive worsening of insulin secretion and, as the name would suggest, neurosensory deafness and maternal inheritance. After three years of treatment with CoQ10 therapy on MIDD patients, progressive hearing loss was prevented and blood sugar metabolites improved after exercise. Furthermore, there were no side effects during therapy.42

Bilberry
One clinician/researcher had this to say about Bilberry (a European relative of the American Blueberry): “Perhaps the most significant clinical applications for bilberry extracts are in the field of ophthalmology.” The health of the eye depends on a rich supply of nutrients and oxygen, and, “Relatively speaking, the amount of blood blow through the eye is the greatest in the body.” Bilberry appears to support vision by improving the delivery of oxygen and blood, “as well as exerting other important pharmacological effects,” including acting as an antioxidant. Among other benefits, Bilberry has proven effective in treating or preventing diabetic retinopathy, and macular degeneration. Bilberry’s strengthening effect on collagen may explain its benefit in helping to treat diabetic retinopathy. It also effectively regulates blood sugar levels in diabetic subjects.43

Inositol
An altered metabolism of inositol, a natural substance associated with the B complex group of vitamins, has been documented in patients with diabetes.44 In fact, over 20 years ago, researchers found that high blood sugar levels in diabetes “may condition a widespread relative intracellular inositol deficiency, and suggest that restoration of normal intracellular inositol concentrations might prove to be of benefit in the prevention and treatment of certain of the complications associated with human diabetes mellitus.”45 As it turned out, supplementation with inositol has indeed proven beneficial for diabetics. For example, low levels of inositol have been associated with neuropathy in diabetic patients, 46 and inositol supplementation has been demonstrated to be effective in treating diabetic neuropathy.47 Another benefit is that supplementation with inositol can help prevent the premature aging of certain cells in the diabetic which is caused by elevated concentrations of blood sugar.48 Other research suggests that inositol may exert a protective effect on slowly developing diabetic cataracts.49

Finally, consider that the incidence of major congenital malformations is approximately 6–9 percent in pregnancies complicated by diabetes mellitus. This incidence is 3–4-fold higher than that in the general population. Congenital malformations are now ranked as the leading cause of death in the offspring of women with diabetes. This particular type of congenital malformation in the offspring of diabetic women is referred to as diabetic embryopathy. Dietary supplementation of inositol has been shown to reduce the incidence of diabetes-related malformations in offspring of diabetic pregnant animals.50 Researchers have indicated that supplementation with inositol offers great promise, in addition to blood sugar control, as a dietary preventive measure against diabetic embryopathy.51

A Word Of Caution
If you are diabetic and controlled on medication, make your health professional aware of any changes you intend to make in your lifestyle. Diet, exercise, and supplements may affect your blood sugar levels. Make your doctor a participant in any changes you would like to make in your health management. This will assure that you are being properly monitored and that you will keep yourself out of trouble.

References:

  1. Davies S, Howard JM, Hunnisett A, et al. Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients—implications for the prevention of cardiovascular disease and type II diabetes. Metabolism 1997;46:469–73.
  2. Morris BW, Kemp GJ, Hardisty CA. Plasma chromium and chromium excretion in diabetes. Clin Chem 1985;31:334–5.
  3. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786–91.
  4. Rabinovitz H, Friedensohn A, Leibovitz A, et al. Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res 2004;74:178–82.
  5. Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006;29:1826–32.
  6. Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006;29:1826–32.
  7. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786–91.
  8. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care 1994;17:1449–52.
  9. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786–91.
  10. Fox GN, Sabovic Z. Chromium picolinate supplementation for diabetes mellitus. J Fam Pract 1998;46:83–6.
  11. Ravina A, Slezak L, Mirsky N, et al. Reversal of corticosteroidinduced diabetes mellitus with supplemental chromium. Diabet Med 1999;16:164–7.
  12. Suzuki Y, Unno T, Ushitani M, et al. Antiobesity activity of extracts from Lagerstroemia speciosa L. leaves on female KKAy mice. Journal of Nutritional Science and Vitaminology 1999; 45(6):791–5.
  13. Hayashi T, Maruyama H, Kasai R, et al. Ellagitannins from Lagerstroemia speciosa as activators of glucose transport in fat cells. Planta medica 2002; 68(2):173–5.
  14. Kakuda T, Sakane I, Takihara T, et al. Hypoglycemic effect of extracts from Lagerstroemia speciosa L. leaves in genetically diabetic KK-AY mice. Bioscience, biotechnology, and biochemistry 1996; 60(2):204–8.
  15. Judy, W. V. Glucosol™ Clinical Study Synopsis (1999) Report from Soft Gel Technologies, Inc.
  16. Judy, W. V. Glucosol™ Clinical Study Synopsis (1999) Report from Soft Gel Technologies, Inc.
  17. Shimizu K, et al, J Vet Med Sci (1997) 59(9):753–7.
  18. Okabayashi Y, et al, Diabetes Res Clin Pract (1990) 9 (2):143–8.
  19. Shanmugasundaram KR, J Ethnopharmacol (1983) 7(2):205–34.
  20. Shanmugasundaram ER, et al, J Ethnopharmacol (1990) 30(3):265–79.
  21. Ibid.
  22. Baskaran K, et al, J Ethnopharmacol (1990) 30(3):295–300.
  23. Shanmugasundaram ER, et al, J Ethnopharmacol (1990) 30(3):281–94.
  24. Welihinda J, et al, J Ethnopharmacol (1986) 17(3):277–82.
  25. Leatherdale BA, et al, Br Med J (1981) 282(6279):1823–4.
  26. Khanna P, et al, J Nat Prod (1981) 44(6):648–55.
  27. Jacob S, et al, Free Radic Biol Med (1999) 27(3-4):309–14.
  28. Ziegler D, et al, Diabetes Care (1999) 22(8):1296–301.
  29. Reljanovic M, et al, Free Radic Res (1999) 31(3):171–9.
  30. Haak ES, et al, Microvasc Res (1999) 58(1):28–34.
  31. Ziegler D, et al, Diabetes Care (1997) 20(3):369–73.
  32. Strokov IA, et al, Zh Nevrol Psikhiatr Im S S Korsakova (1999) 99(6):18–22.
  33. Ziegler D, et al, Diabetes (1997) 46 Suppl 2:S62–6.
  34. Ziegler D, et al, Diabetologia (1995) 38(12):1425–33.
  35. Roy S, et al, Biochem Pharmacol (1997) 53(3):393–9.
  36. Borcea V, et al, Free Radic Biol Med (1999) 26(11-12):1495–500.
  37. Jacob S, et al, Arzneimittelforschung (1995) 45(8):872–4.
  38. Konrad T, et al, Diabetes Care (1999) 22 (2):280–7.
  39. Kishi T, et al, J Med (1976) 7(3-4):307–21.
  40. Miyake Y, et al, Arzneimittelforschung (1999) 49(4):324–9.
  41. Fujioka T, Sakamoto Y, Mimura G, Tohoku J Exp Med (1983) 141 Suppl:453–63.
  42. Suzuki S, Diabetologia (1998) 41(5):584–8.
  43. Murray M, American Journal of Natural Medicine (1997) 4(1):18–22.
  44. Holub BJ, Adv Nutr Res (1982) 4:107–41.
  45. Clements RS Jr, Reynertson R, Diabetes (1977) 26(3):215–21.
  46. Servo C, Bergstrom L, Fogelholm R, Acta Med Scand (1977) 202(4):301–4.
  47. Pfeifer MA, Schumer MP, Diabetes (1995) 44(12):1355–61.
  48. Sibbitt WL Jr, et al, Mech Ageing Dev (1989) 47(3):265–79.
  49. Beyer-Mears A, et al, Pharmacology (1989) 39(1):59–68.
  50. Reece EA, et al, J Soc Gynecol Investig (1998) 5(4):178–87.
  51. Reece EA, Homko CJ, Wu YK, Teratology (1996) 54(4):171–82.